Mental Health Care (UK) Ltd

mentalhealthcare-uk.com

Mental Health Care UK (MHC) is one of the UK’s top 50 providers of support to individuals with learning disabilities,mental health issues, behaviours that challenge and autism. In our calm and safe residential homes and hospitals we believe in a research based approach to our services. Residents with learning disabilities, behaviours that challenge, mental health issues, and autism will benefit from an approach that uses Active Support, Person Centred Planning and Positive Behavioural Support to enable our residents to be in control, make decisions and achieve what’s important for them.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

NAVIGATE BIOPHARMA SERVICES, INC. LAUNCHES NEW MULTIPLEX DIGITAL PCR ASSAY FOR COMPREHENSIVE QUANTIFICATION OF UP TO 5 DIFFERENT CAR-T TRANSGENES

PRNewswire | June 02, 2023

news image

During this year's AAPS National biotechnology conference, Navigate BioPharma Services, Inc., a Novartis subsidiary and a leading provider of innovative biomarker solutions for drug development, announced the launch of its new multiplex digital PCR assays for comprehensive quantification of multiple chimeric antigen receptor (CAR) T cells, a type of cancer immunotherapy that involves genetically modifying T cells to recognize and destroy certain cancers. These assays are based on the Q...

Read More

Industrial Impact

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS TARGETING

FogPharma | November 22, 2022

news image

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant...

Read More

Cell and Gene Therapy

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

news image

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More

Cell and Gene Therapy

MODERNA AND AUSTRALIA ANNOUNCE COLLABORATION TO BRING MRNA MANUFACTURING TO AUSTRALIA

Moderna | December 14, 2021

news image

Moderna, Inc. a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement in principle with the Australian Government to build a state-of-the-art messenger RNA vaccine manufacturing facility in Victoria, Australia including access to Moderna’s mRNA development engine. The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vacci...

Read More
news image

Medical

NAVIGATE BIOPHARMA SERVICES, INC. LAUNCHES NEW MULTIPLEX DIGITAL PCR ASSAY FOR COMPREHENSIVE QUANTIFICATION OF UP TO 5 DIFFERENT CAR-T TRANSGENES

PRNewswire | June 02, 2023

During this year's AAPS National biotechnology conference, Navigate BioPharma Services, Inc., a Novartis subsidiary and a leading provider of innovative biomarker solutions for drug development, announced the launch of its new multiplex digital PCR assays for comprehensive quantification of multiple chimeric antigen receptor (CAR) T cells, a type of cancer immunotherapy that involves genetically modifying T cells to recognize and destroy certain cancers. These assays are based on the Q...

Read More
news image

Industrial Impact

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS TARGETING

FogPharma | November 22, 2022

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant...

Read More
news image

Cell and Gene Therapy

EIGER BIOPHARMACEUTICALS PROVIDES UPDATE ON PLANS FOR EMERGENCY USE AUTHORIZATION APPLICATION FOLLOWING FDA FEEDBACK

Eiger BioPharmaceuticals, Inc. | October 06, 2022

Eiger BioPharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration the company will not submit an emergency use authorization application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19. Following Eiger's press release on September 6, 2022, the c...

Read More
news image

Cell and Gene Therapy

MODERNA AND AUSTRALIA ANNOUNCE COLLABORATION TO BRING MRNA MANUFACTURING TO AUSTRALIA

Moderna | December 14, 2021

Moderna, Inc. a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced an agreement in principle with the Australian Government to build a state-of-the-art messenger RNA vaccine manufacturing facility in Victoria, Australia including access to Moderna’s mRNA development engine. The contemplated framework would build the foundation to support Australia with direct access to rapid pandemic response capabilities and to provide access to Moderna’s vacci...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us